Thyroid Dysfunction and Atrial Fibrillation Risk in Hypertrophic Cardiomyopathy Patients

A multicenter retrospective cohort of 755 patients with hypertrophic obstructive cardiomyopathy from three tertiary centers between 2019 and 2024. The dataset, created by Weijie Zhang and last updated in April 2026, includes patient thyroid-stimulating hormone levels and incident atrial fibrillation events over a 12-month follow-up period.

Use Cases

• Assessing the association between thyroid-stimulating hormone levels and atrial fibrillation risk based on patient cohort data.
• Performing risk stratification for atrial fibrillation in hypertrophic cardiomyopathy patients based on thyroid function status.
• Validating statistical models for clinical outcomes using multivariable logistic and Cox regression results described in the study.

Strengths

• Includes data from 755 consecutive patients across three tertiary centers.
• Provides a 12-month follow-up period with 107 incident atrial fibrillation events (14.2% cumulative incidence).
• Analysis includes multivariable adjustment and sensitivity analysis using Cox regression.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is contained in a single 10.2 KB DOCX file, suggesting limited scope and potentially summarized results rather than raw patient-level data.

Provenance

Source

Weijie Zhang via figshare.

Collection Method

Retrospective analysis of consecutive patients from three tertiary centers.

Time Range

2019–2024, with a 12-month follow-up period.

Freshness

Last updated 2026-04-17 04:11:46; freshness should be verified.

Geography

Data likely originates from three tertiary centers; specific geographic locations are not stated.